HomePipelinePNB-081

Metabolic & opiate programme

PNB-081

Preclinical completed · IND ready

A closely related molecule addressing Obesity at low doses and, at higher doses, acting as an opiate-sparing agent. It may also substitute for PNB-028 in Pancreatitis.

Indications

Each indication opens its study.

Metabolic Diseases

CNS & addiction

Stage of development

  • PNB-081

    ObesityCCK-mediated reduction of food intake

  • PNB-081

    Opiate ManagementCCK-A antagonist

Graph of the stage of development of each PNB-081 programme. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.
Target and mechanism
CCK-A (CCK1) antagonist, with a binding profile equivalent to devazepide. Developed from PNB-001.
Key findings

In metabolic-cage studies, food intake in rats fell from day 2 onwards, by up to 50% (group of six rats). A 2 mg/kg dose lowered blood glucose in the glucose tolerance test.

Given orally at 1 mg/kg in mice alongside 4 mg/kg morphine, it prevented the development of morphine tolerance over many days.

Also effective in preclinical models of Pancreatitis, depression and anxiety.

Development

Orally bioavailable, with very high membrane penetration and favourable CaCo-2 permeability and plasma protein binding.

Intellectual property
Protected until 2037, including a five-year extension, in most countries.

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.